NCI’s PRICING PARADIGM FOR CRADAs: ENTRY PRICES MUST BE IN LINE WITH EXISTING DRUGS, ADDED INDICATIONS SHOULD LOWER PRICES; FREE SUPPLIES IMPORTANT ALSO

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".